Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Health Promot Perspect ; 12(2): 192-199, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-2057088

RESUMEN

Background: The Japanese government advised mild or asymptomatic coronavirus disease-2019 (COVID-19) cases to self-isolate at home, while more severe individuals were treated at health posts. Poor compliance with self-isolation could be a potential reason for the new outbreak. Our study aimed to find out the correlation between the rising new cases of COVID-19 and home-based patients in Japan. Methods: A secondary data analysis study was conducted with the data from COVID-19- involved databases collected from Johns Hopkins University, Japanese Ministry of Health, Labour and Welfare, and Community Mobility Reports of Google. New community cases, stringency index, number of tests, and active cases were analyzed. Using a linear regression model, an independent variable was utilized for a given date to predict the future number of community cases. Results: Research results show that outpatient cases, the stringency, and Google Mobility Trend were all significantly associated with the number of COVID-19 community cases from the sixth day to the ninth day. The model predicting community cases on the eighth day (R2=0.8906) was the most appropriate showing outpatients, residential index, grocery and pharmacy index, retail and recreation index, and workplaces index were positively related (ß1=24.2, 95% CI: 20.3- 26.3, P<0.0001; ß2=277.7, 95% CI: 171.8-408.2, P<0.0001; ß3=112.4, 95% CI: 79.8-158.3, P<0.0001; ß4=73.1, 95% CI: 53- 04.4, P<0.0001; ß5=57.2, 95% CI: 25.2-96.8, P=0.001, respectively). In contrast, inpatients, park index, and adjusted stringency index were negatively related to the number of community cases (ß6=-2.8, 95% CI: -3.9 - -1.6, P<0.0001; ß7=-33, 95% CI: -43.6 - -27, P<0.0001; ß8=-14.4, 95% CI: -20.1- -12, P<0.0001, respectively). Conclusion: Outpatient cases and indexes of Community Mobility Reports were associated with COVID-19 community cases.

2.
Rev Med Virol ; 31(6): e2288, 2021 11.
Artículo en Inglés | MEDLINE | ID: covidwho-1384306

RESUMEN

SARS Coronavirus-2 is one of the most widespread viruses globally during the 21st century, whose severity and ability to cause severe pneumonia and death vary. We performed a comprehensive systematic review of all studies that met our standardised criteria and then extracted data on the age, symptoms, and different treatments of Covid-19 patients and the prognosis of this disease during follow-up. Cases in this study were divided according to severity and death status and meta-analysed separately using raw mean and single proportion methods. We included 171 complete studies including 62,909 confirmed cases of Covid-19, of which 148 studies were meta-analysed. Symptoms clearly emerged in an escalating manner from mild-moderate symptoms, pneumonia, severe-critical to the group of non-survivors. Hypertension (Pooled proportion (PP): 0.48 [95% Confident interval (CI): 0.35-0.61]), diabetes (PP: 0.23 [95% CI: 0.16-0.33]) and smoking (PP: 0.12 [95% CI: 0.03-0.38]) were highest regarding pre-infection comorbidities in the non-survivor group. While acute respiratory distress syndrome (PP: 0.49 [95% CI: 0.29-0.78]), (PP: 0.63 [95% CI: 0.34-0.97]) remained one of the most common complications in the severe and death group respectively. Bilateral ground-glass opacification (PP: 0.68 [95% CI: 0.59-0.75]) was the most visible radiological image. The mortality rates estimated (PP: 0.11 [95% CI: 0.06-0.19]), (PP: 0.03 [95% CI: 0.01-0.05]), and (PP: 0.01 [95% CI: 0-0.3]) in severe-critical, pneumonia and mild-moderate groups respectively. This study can serve as a high evidence guideline for different clinical presentations of Covid-19, graded from mild to severe, and for special forms like pneumonia and death groups.


Asunto(s)
COVID-19/patología , Tos/patología , Disnea/patología , Fatiga/patología , Fiebre/patología , SARS-CoV-2/patogenicidad , Antivirales/uso terapéutico , COVID-19/mortalidad , COVID-19/virología , Comorbilidad , Tos/tratamiento farmacológico , Tos/mortalidad , Tos/virología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/fisiopatología , Disnea/tratamiento farmacológico , Disnea/mortalidad , Disnea/virología , Fatiga/tratamiento farmacológico , Fatiga/mortalidad , Fatiga/virología , Fiebre/tratamiento farmacológico , Fiebre/mortalidad , Fiebre/virología , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Factores Inmunológicos/uso terapéutico , Pronóstico , Síndrome de Dificultad Respiratoria/diagnóstico , Síndrome de Dificultad Respiratoria/fisiopatología , Índice de Severidad de la Enfermedad , Fumar/fisiopatología , Análisis de Supervivencia , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA